Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative and Absolute Bioavailability Study of ACE910 (emicizumab) in Healthy Adult Male Volunteers
jRCT2080222836Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Relative and absolute bioavailability of emicizumab. Started Apr 2015; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080222836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222836.